current user: public

If you have questions about the server, please let us know.

Query: sp|Q29940|1B59_HUMAN(removed signalp:1-24) HLA class I histocompatibility antigen, B-59 alpha chain OS=Homo sapiens GN=HLA-B PE=2 SV=1, from H.sapiens

Results of FFAS03 search in PfamA32U
Master-slave alignment(slide right to see more) does not show gaps in the query sequence, use ali links to display alignment between query and templates.
    .   10    .   20    .   30    .   40    .   50    .   60    .   70    .   80    .   90    .  100    .  110    .  120    .  130    .  140    .  150    .  160    .  170    .  180    .  190    .  200    .  210    .  220    .  230    .  240    .  250    .  260    .  270    .  280    .  290    .  300    .  310    .  320    .  330    .
# Score Template Links and tools%idFirst GSHSMRYFYTAMSRPGRGEPRFIAVGYVDDTQFVRFDSDAASPREEPRAPWIEQEGPEYWDRNTQIFKTNTQTYRENLRIALRYYNQSEAGSHTWQTMYGCDLGPDGRLLRGHNQLAYDGKDYIALNEDLSSWTAADTAAQITQRKWEAARVAEQLRAYLEGTCVEWLRRYLENGKETLQRADPPKTHVTHHPISDHEATLRCWALGFYPAEITLTWQRDGEDQTQDTELVETRPAGDRTFQKWAAVVVPSGEEQRYTCHVQHEGLPKPLTLRWEPSSQSTIPIVGIVAGLAVLAVVVIGAVVATVMCRRKSSGGKGGSYSQAASSDSAQGSDVSLTALast
1 -62.800PF00129.18; HA10_MOUSE/25-203; Class I Histocompatibility antigen, domains alpha 1 and 2  ali follow..  73  1GSHSMRYFETSVSRPGLGEPRFIIVGYVDDTQFVRFDSDAETPRMEPRAPWMEQEGPEYWERETQRAKGNEQSFHVSLRTLLGYYNQSESGSHTIQWMYGCKVGSDGRFLRGYLQYAYDGRDYIALNEDLKTWTAADVAAIITRRKWEQAGAAEYYRAYLEAECVEWLLRYLELGKETL............................................................................................................................................................... 179
2 -49.200PF14586.6; RAE1C_MOUSE/31-204; Class I Histocompatibility antigen, NKG2D ligand, domains 1 and 2  ali follow..  16  2.AHSLRCNLTIKAPTPADPLWYEAKCLVDEILILHLSNINKTMTSGD--PGETANATEVGECLTQPVNDLCQKLRDKVSNTKVDTHKTNGYPHLQVTM--IYPQSQGQTPSATWEFNISDSYFFTFYTENMSWRSANDESGVIMNKWNDDGDLVQRLKYFIPECRQKIDEFLKQSKEK................................................................................................................................................................ 174
3 -40.200PF16497.5; G1L1W7_AILME/2-199; MHC-I family domain  ali follow..  14  24EPISLRIILTSSF-YNRSRTQNLASAWLDELQTHGWDSKTGAFIFLWP-WSRGNLSNEEVIRAEEAFYSNSIGLPLCFHDHFSEWQLEYP---FQVQLTGGCELHFGEPSVGFIRIAYEGSDLVSFQNMSWWPSEGGSRAQQVCRLFNQDHEDNELMHKLITDHCPRYLSSLLDAGKA................................................................................................................................................................ 197
4 -36.100PF07654.15; H9GZQ9_HORSE/236-322; Immunoglobulin C1-set domain  ali follow..  23  7.............................................................................................................................................................................................HPDELSKSKVSVTCLVKDFYPPEINIEWQSNGQPELETYSTTQAQQDSDGSYFLYSKLSVDRNRGTTFTCGVMHEAL........................................................................ 87
5 -33.600PF15028.6; A0A2I3G3P5_NOMLE/20-146; Pre-T-cell antigen receptor  ali follow..  15  2....................................................................................................................................................................................VGGTLFPSLMLLVDGKQQMVVVCLVLDVAPPGFNPIWFSAGNGSALDAFTYGPSPATDGTWTNLAHLSLPSEEWEPLVCHTRPGAEGHSRSTQPLQLSGEASTARTC................................................... 116
6 -24.200PF05790.15; Q9GKR2_BOVIN/422-510; Immunoglobulin C2-set domain  ali follow..  13  1......................................................................................................................................................................................................VTVSCRVPNVYPDQLEIELFKGESIMMNKTFSKD--VSKKALETKSLEKTFIPTTEDVLVCLARLPIDEMEFELKQRQSTQTLY........................................................ 86
7 -22.400PF08205.12; BCAM_BOVIN/150-248; CD80-like C2-set immunoglobulin domain  ali follow..  12  1........................................................................................................................................................................................PEVSPNKGMDDFAQEIATCSSRNGNPAP-QIMWYRNGQPLAEGYMTTRTVREASGLLSLTSTLYLRLHKPDRFHCSVHYYLPAGQ..................................................................... 98
8 -22.300PF00047.25; OX2G_MOUSE/143-229; Immunoglobulin domain  ali follow..  16  1.........................................................................................................................................................................................PIVHLHYNYFEDHLNITCSATA-RPAP-AISWKGTGTGIENST---ESHFHSNGTTSVTSILRVKDQVGKEVICQVLYLGNVIDYKQSL................................................................ 87
9 -21.300PF09085.10; H0WQ95_OTOGA/112-222; Adhesion molecule, immunoglobulin-like  ali follow..  10  3......................................................................................................................................................................................PDQLTVSPATLVPGVDQEVACTAHKVTPDALSFSLILGDRELEGPEIEEEPQEDEDLLFHVTQRWLLPPPILPNLYCQATMRLPGLELSRH................................................................. 105
10 -16.700PF08204.11; Q9Q8V0_RFVKA/10-120; CD47 immunoglobulin-like domain  ali follow..  15  18.........................................................................................................................................................................................KVTVMPYTVCNTTITLECNLDELIYNSIHVKWLFYTMDDT----------ISNITNGSFIKFDFAKNLSGNYTCEAYSDLNSVKNVIALN............................................................... 100
11 -16.200PF05566.12; IL18B_VACCW/1-126; Orthopoxvirus interleukin 18 binding protein  ali follow..  14  20.......................................................................................................................................................................................ADEIKCPNLNIVTSSGEFRCTGCKFMPNFSYMYWLAKDMRSDEDAKFIEHLGEGGRIVTLQKVLDTNKFDNYRFTCVLTTIDGVSKKNIWLK............................................................... 126
12 -14.300PF13927.6; H9IS41_BOMMO/56-136; Immunoglobulin domain  ali follow..  18  1.......................................................................................................................................................................................PPIVRVEPKNIEGSKLLLKCEYESNPSSLSAVFWFRDGERVNVNDTAH--YQGGTTDQHSLIIMNARGVDMGNYTCLLTN........................................................................... 81
13 -13.000PF13895.6; F6QPE0_BOVIN/327-404; Immunoglobulin domain  ali follow..  18  1.......................................................................................................................................................................................KPKLESSATHLDQGELNLWCSIPG-APP-ANFTIQKGSMTVSQTQN---------------FTKRVSEWDSGLYTCVAGVFKRSNTVQIT................................................................. 77
14 -13.000PF17736.1; A0A096NT62_PAPAN/27-121; C17orf99 Ig domain  ali follow..  10  1........................................................................................................................................................................................PVVSIAYKVPKGRRVLITCHAPQASPPITYSLCGTKNIEVAKKVVKTHEPASFNLNIT-----LKSSPDLLTYFCRAATTVDSARLQMYWE............................................................... 94
15 -11.400PF07686.17; A2BGB5_DANRE/30-142; Immunoglobulin V-set domain  ali follow..  16  6...............................................................................................................................................................................................EAVNGTEIRLKCTFKSNRPERTSVSWSFPGGLFKDHVVWSGDVMKGDGSITLQ---DVQFSFNGTYSCQVLNPP......................................................................... 100
16 -11.200PF16681.5; F1SAK8_PIG/36-116; Ig-like domain on T-cell surface glycoprotein CD3 epsilon chain  ali follow..  17  6..................................................................................................................................................................................................SGDKVELTCPEDP---ESEKMTWKRNDMQIYESYDNYMLLES-----------FSEVENSGYYTCTVGEK.......................................................................... 61
17 -10.500PF07679.16; Q9GV22_MYTGA/647-736; Immunoglobulin I-set domain  ali follow..  13  11...............................................................................................................................................................................................SLNEGDRLKLTCTVKG-QPEP-EVEWFYNGQLMQSD---DAIKISAIAGHHTLTIDSCIIDDDGNYVCKAKNP.......................................................................... 78
18 -10.100PF16706.5; IZUM1_RAT/168-255; Izumo-like Immunoglobulin domain  ali follow..  4...............................................................................................................................................................................................EVHRLEDMVLDCQLSW--HHASEGLTDYSFYRVWGNSSETLMSKGKEPYLTKT---MVGPEDAGNYRCELDTVNAGPATIIYYH............................................................... 82
19 -10.100PF02440.15; Q6QPD0_9ADEN/15-113; Adenovirus E3 region protein CR1  ali follow..  15  1.........................................................................................................................................................................................ALCESVDRDVTITTGSNYTLKG-PPSG-MLSWYCYFGTDTDQTELCNNYQCNGTDLIL---LNVTKAYGGSYYCPGQNT.......................................................................... 86
20 -9.640PF00969.19; Q3UUV9_MOUSE/43-114; Class II histocompatibility antigen, beta domain  ali follow..  2....................................................................................................CHYFNGKERVWSVTRFIYNQEEFARFNSDFGKFLAVTELGRPIVEYLNTQKDMLDNYRASVDRC.............................................................................................................................................................................. 65
21 -9.620PF15910.5; A0A287A7M9_PIG/23-135; ICOS V-set domain  ali follow..  9...............................................................................................................................................................................................FMFHDGGLQIVCKYPD---RQFKMQLLKGKNILTNVNLCQFQLSNNSVSFFLY---NLDSSYASYYICELS............................................................................ 90
22 -9.470PF06623.11; F7C2F9_HORSE/248-275; MHC_I C-terminus  ali follow..  73  1........................................................................................................................................................................................................................................................................................................................SGREGRSYTQAAGSDSAQGSDVSLMD 26

FFAS is supported by the NIH grant R01-GM087218-01
1 3 6 9 2 4   jobs submitted since Jan 1, 2011
Comments and questions to: webmaster

Selected papers from Godzik Lab
Ying Zhang, Ines Thiele, Dana Weekes, Zhanwen Li, Lukasz Jaroszewski, Krzysztof Ginalski, Ashley Deacon, John Wooley, Scott Lesley, Ian Wilson, Bernhard Palsson, Andrei Osterman, Adam Godzik. Three-Dimensional Structural View of the Central Metabolic Network of Thermotoga maritima. Science. 2009 Sep 18;325(5947):1544-9.

Mayya Sedova, Mallika Iyer, Zhanwen Li, Lukasz Jaroszewski, Kai W Post, Thomas Hrabe, Eduard Porta-Pardo, Adam Godzik Cancer3D 2.0:: interactive analysis of 3D patterns of cancer mutations in cancer subsets. Nucleic Acids Research, gky1098 2018; Published on November 8 2018.

Shiryaev SA, Ratnikov BI, Chekanov AV, Sikora S, Rozanov DV, Godzik A,Wang J, Smith JW, Huang Z, Lindberg I, Samuel MA, Diamond MS, Strongin AY. Cleavage targets and the D-arginine-based inhibitors of the West Nile virus NS3 processing proteinase. Biochem J. 2006 Jan 15;393(Pt 2):503-11.